Want to see ALKS full AI Analyst Report?
ALKS Stock Chart & Stats
$34.53
-$0.20(-0.70%)
At close: 4:00 PM EST
$34.53
-$0.20(-0.70%)
Day’s Range― - ―
52-Week Range$25.17 - $55.67
Previous CloseN/A
Volume176.14K
Average Volume (3M)2.33M
Market Cap
$8.79B
Enterprise Value$6.95K
Total Cash (Recent Filing)$511.86M
Total Debt (Recent Filing)$1.58B
Price to Earnings (P/E)56.7
Beta0.67
Next Earnings
Jul 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding166,675,810
10 Day Avg. Volume1,525,229
30 Day Avg. Volume2,331,288
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$53.92Price Target Upside56.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.38
Revenue Forecast (FY)$1.81B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & ProfitabilityVery high gross margins (~85–86% TTM) reflect a high-margin proprietary product mix and durable manufacturing economics. Sustained margin advantage provides pricing power and cash generation capacity to fund R&D and commercialization while insulating core profitability from moderate revenue variability.
Positive Operating And Free Cash FlowConsistent positive OCF (~$256M) and FCF (~$222M) demonstrate the business converts sales into cash, supporting debt servicing, share repurchases and pipeline investment. Persistent cash generation underpins financial flexibility despite cyclical R&D spend and acquisition activity.
Commercial Momentum & Pipeline ProgressRobust commercial growth (+38% YoY) plus an early, sizable LUMRYZ launch and active orexin Phase III programs create multiple durable growth levers. Launch momentum and a progressing pipeline diversify future revenue streams and improve the company's medium-term growth profile beyond legacy royalties.
Bears Say
Sharp Rise In LeverageA large increase in term debt materially reduces financial flexibility and raises interest and covenant risk. Higher leverage limits strategic optionality, increases sensitivity to execution or revenue shortfalls, and lengthens the runway needed for deleveraging even with positive cash flow.
Weakened Free-cash-flow MomentumWhile FCF is positive, a sharp drop in FCF growth and lower OCF-to-net-income conversion indicate worsening cash quality or higher working-capital and one-off uses. This weakens the firm's ability to sustainably fund R&D, M&A integration and debt reduction without relying on external financing.
Elevated Operating Costs And GAAP LossRising R&D and SG&A—partly from program scale-up and acquisition integration—are pressuring GAAP profitability and free-cash-flow conversion. Persistent elevated operating costs could prolong GAAP losses or compress margins if revenue growth decelerates, limiting reinvestment or deleveraging capacity.
Alkermes News
ALKS FAQ
What was Alkermes plc’s price range in the past 12 months?
Alkermes plc lowest stock price was $25.16 and its highest was $55.67 in the past 12 months.
What is Alkermes plc’s market cap?
Alkermes plc’s market cap is $8.79B.
When is Alkermes plc’s upcoming earnings report date?
Alkermes plc’s upcoming earnings report date is Jul 28, 2026 which is in 9 days.
How were Alkermes plc’s earnings last quarter?
Alkermes plc released its earnings results on May 05, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.146.
Is Alkermes plc overvalued?
According to Wall Street analysts Alkermes plc’s price is currently Undervalued.
Does Alkermes plc pay dividends?
Alkermes plc does not currently pay dividends.
What is Alkermes plc’s EPS estimate?
Alkermes plc’s EPS estimate is -0.02.
How many shares outstanding does Alkermes plc have?
Alkermes plc has 166,675,810 shares outstanding.
What happened to Alkermes plc’s price movement after its last earnings report?
Alkermes plc reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went up 6.087%.
Which hedge fund is a major shareholder of Alkermes plc?
Currently, no hedge funds are holding shares in ALKS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$53.92 (56.14% Upside)
$53.92 (56.14% Upside)
Blogger Sentiment
Bullish
ALKS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $687.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.3%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
79.56%
12-Months-Change
Fundamentals
Return on Equity
8.82%
Trailing 12-Months
Asset Growth
104.52%
Trailing 12-Months
Company Description
Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
ALKS Stock 12 Month Forecast
Average Price Target
$53.92
▲(56.14% Upside)
Technical Analysis
Ownership Overview
1.43% Insiders
26.14% Mutual Funds
0.22% Other Institutional Investors
40.47% Public Companies and
Individual Investors